Free Newsletter
Quark, Nitto Denko collaborate on fibrotic diseases
Quark Pharmaceuticals, a Fremont, CA-based developer of RNAi-based therapeutics, is collaborating with Nitto Denko, a diversified materials manufacturer based in Osaka, Japan, to develop siRNA therapeutics to treat fibrotic diseases. Quark will provide the RNAi technology and Nitto Denko will work on drug delivery. The two companies are aiming for an Investigational New Drug designation by the FDA by early 2012. Release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: